Multidrug-resistant Pseudomonas aeruginosa nosocomial infections are increasingly recognized worldwide. The existence of metallo--lactamase-and extended-spectrum -lactamase-producing isolates exhibiting resistance to most -lactam antimicrobial agents greatly complicates the clinical management of patients infected with such isolates. Since 1998, P. aeruginosa isolates resistant to all commercially available antimicrobial agents have been detected at a university-affiliated public hospital in Rio de Janeiro, Brazil. The present study was designed to characterize the antimicrobial resistance profiles and the genetic diversity of the P. aeruginosa strains isolated at this hospital and four private hospitals in Rio de Janeiro. Between April 1999 and March 2000, 200 consecutive isolates were obtained and analyzed for antimicrobial resistance. The genetic diversity of a selected number of them was evaluated by pulsed-field gel electrophoresis and PCR with the ERIC-2 primer. A predominant genotype, designated genotype A, was identified among isolates from four of the five hospitals evaluated. Eighty-four ceftazidime-resistant isolates were evaluated for metallo--lactamase production, which was detected in 20 (91%) of 22 genotype A isolates and 11 (18%) of 62 isolates belonging to other genotypes (P < 0.05). Two metallo--lactamase-producing genotype A isolates also produced an extended-spectrum -lactamase. The occurrence of multidrug-resistant P. aeruginosa strains belonging to a unique genotype in different hospitals in Rio de Janeiro underscores the importance of the contribution of a single clone to the increase in the incidence of multidrug-resistant P. aeruginosa nosocomial infections.
Change in epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) was observed because of the emergence of infections by non-multiresistant MRSA (nMRSA) in our hospital in Rio de Janeiro, Brazil. Clinical characterization and molecular analysis of 20 nMRSA isolates recovered from 17 patients, between February 2005 and March 2006, were performed. The analysis included SCCmec (staphylococcal cassette chromosome mec), pulsed field gel electrophoresis (PFGE), multilocus restriction fragment, and multilocus sequence typing. MICs for oxacillin and vancomycin and presence of Panton-Valentine leukocidin (PVL) genes were also investigated. All but 1 of the 20 isolates presented SCCmec type IV. PFGE clustered all isolates into 9 genotypes. MIC < or = 16 microg/mL to oxacillin was found for 65% of the isolates, whereas 80% exhibited MIC of 2 microg/mL for vancomycin. PVL-encoding genes were observed in 3 isolates. Polyclonal presence of nMRSA SCCmec IV was observed in our institution, including community and health care-associated isolates, which belonged to the sequence types (STs) 1 (clonal complex [CC1]), ST5 (CC5), ST8 and ST72 (CC8), ST97 (CC97), and 2 ST singletons (SLV5 and SLV30).
BackgroundInfection with carbapenem-resistant Acinetobacter baumannii has been associated with high morbidity and mortality in solid organ transplant recipients. The main objective of this study was to assess the influence of carbapenem resistance and other potential risk factors on the outcome of A. baumannii infection after kidney and liver transplantation.MethodsRetrospective study of a case series of A. baumannii infection among liver and renal transplant recipients. The primary outcome was death associated with A. baumannii infection. Multivariate logistic regression was used to assess the influence of carbapenem resistance and other covariates on the outcome.ResultsForty-nine cases of A. baumannii infection affecting 24 kidney and 25 liver transplant recipients were studied. Eighteen cases (37%) were caused by carbapenem-resistant isolates. There were 17 (35%) deaths associated with A. baumannii infection. In unadjusted analysis, liver transplantation (p = 0.003), acquisition in intensive care unit (p = 0.001), extra-urinary site of infection (p < 0.001), mechanical ventilation (p = 0.001), use of central venous catheter (p = 0.008) and presentation with septic shock (p = 0.02) were significantly related to a higher risk of mortality associated with A. baumannii infection. The number of deaths associated with A. baumannii infection was higher among patients infected with carbapenem-resistant isolates, but the difference was not significant (p = 0.28). In multivariate analysis, the risk of A. baumannii-associated mortality was higher in patients with infection acquired in the intensive care unit (odds ratio [OR] = 34.8, p = 0.01) and on mechanical ventilation (OR = 15.2, p = 0.04). Appropriate empiric antimicrobial therapy was associated with significantly lower mortality (OR = 0.04, p = 0.03), but carbapenem resistance had no impact on it (OR = 0.73, p = 0.70).ConclusionThese findings suggest that A. baumannii-associated mortality among liver and kidney transplant recipients is influenced by baseline clinical severity and by the early start of appropriate therapy, but not by carbapenem resistance.
In this article, we report a case series of patients with infections caused by Enterobacteriales coresistant to carbapenems and polymyxins who were treated with ceftazidime/avibactam (CAZ-AVI) salvage therapy on a compassionate-use protocol. We enrolled 29 adult patients in 3 centers that had an infection due to a resistant microorganism and for whom the treatments available were considered ineffective, treated them with CAZ-AVI, and assessed clinical and microbiological cure at the end of treatment and all-cause mortality at 14 days and 30 days. The antimicrobial susceptibility profile was determined using broth microdilution, and total genomic DNA was sequenced. Twelve (41.4%) patients had bacteremia, and 48.3% (14/29) of the infections were treated with combination therapy. All strains were producers of KPC-2 and were susceptible to CAZ-AVI (MIC90, 1 μg/ml). Clinical success was high (24/29 [82.7%; 95% confidence interval, 64.2 to 94.2%]), even for the bacteremic cases (75%). The 14-day and 30-day mortality rates were 9/29 (31%) and 15/29 (51.7%), respectively. The 14-day mortality rate for pneumonia was the same as that for bloodstream infections (33.3%) and although not significant, we found that patients with renal impairment that received adjusted doses of CAZ-AVI had high mortality (4/9 [44%]; P = 0.22). We concluded that CAZ-AVI is an option for the treatment of severe infections due to difficult-to-treat drug-resistant Enterobacteriales.
M ethicillin-resistant Staphylococcus aureus (MRSA) is characterized by the mainly clonal structure of bacterial populations and the worldwide spread of a few highly successful lineages, sequence types (STs), and clonal complexes (CCs) that cycle through waves of dominance (1,2). During the late 1990s, the Brazilian endemic clone (BEC), which belongs to the ST239(CC8)-staphylococcal cassette chromosome (SCC) mecIII lineage, comprised ≈80% of MRSA isolates in hospitals in Brazil (3). In the 2000s, isolates of the ST1(CC1)-SCCmecIV lineage supplanted BEC in >2 hospitals in the Rio de Janeiro metropolitan area of Brazil (4). More recent analyses have suggested that CC5 isolates might be increasing in prevalence in Brazil (5).Most studies on the molecular epidemiology of MRSA in Brazil have analyzed a small number of isolates from a limited number of hospitals (5-9). We used molecular and genomic approaches to characterize 600 MRSA isolates collected from 51 hospitals in the Rio de Janeiro metropolitan area and identifi ed a novel MRSA clone of ST105-SCCmecII spa t002 (ST105-SCCmecII-t002), which we termed the Rio de Janeiro (RdJ) clone, as a predominant cause of MRSA bloodstream infections (BSIs).
After mupirocin use decreased, the ileS-2 encoding plasmid persisted in only a few Brazilian clone isolates. Our data on mupirocin-resistant MRSA incidence and mupirocin use strongly suggested that restricted use was related to decreased rates of mupirocin resistance at our hospital.
Carbapenem-resistance mechanisms are a challenge in the treatment of
Pseudomonas aeruginosa infections. We investigated changes in
P. aeruginosa carbapenem-resistance determinants over a time
period of eight years after the emergence of São Paulo metallo-β-lactamase in a
university hospital in Rio de Janeiro, Brazil. Patients admitted to the intensive
care unit (ICU) were screened for P. aeruginosa colonisation and
followed for the occurrence of infections from April 2007 to April 2008. The ICU
environment was also sampled. Isolates were typed using random amplified polymorphic
DNA, pulsed-field gel electrophoresis and multilocus sequence typing. Antimicrobial
susceptibility was determined by disk diffusion and E-test, production of
carbapenemases by a modified-CarbaNP test and presence of carbapenemase-encoding
genes by polymerase chain reaction. Non-carbapenemase resistance mechanisms studied
included efflux and AmpC overexpression by PAβN and cloxacillin susceptibility
enhancement, respectively, as well as oprD mutations. From 472
P. aeruginosa clinical isolates (93 patients) and 17 isolates
from the ICU environment, high genotypic diversity and several international clones
were observed; one environment isolate belonged to the blaSPM-1
P. aeruginosa epidemic genotype. Among isolates from infections,
10 (29%) were carbapenem resistant: none produced carbapenemases, three exhibited all
non-carbapenemase mechanisms studied, six presented a combination of two mechanisms,
and one exclusively displayed oprD mutations. Carbapenem-resistant
P. aeruginosa displayed a polyclonal profile after the SPM-1
epidemic genotype declined. This phenomenon is connected with
blaSPM-1 P. aeruginosa replaced by other
carbapenem-resistant pathogens.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.